Navigation Links
Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
Date:7/31/2009

CARLSBAD, Calif., July 31 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of skin scarring and fibrotic disorders, is pleased to announce that Jay Birnbaum, Ph.D. has joined the Board of Directors as an Independent Board Member.

Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, medical devices, and cosmeceuticals. His 35 years of industry experience span the areas of discovery research, formulations, clinical R&D, regulatory and marketing, and he has been involved in the development and commercialization of numerous drug and consumer products and brands. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals, a company developing products in aesthetic dermatology. Prior to starting his own consulting company in 1999, he was with Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President, Global Project Management, with responsibilities for strategic planning and development of the company's dermatology portfolio. Prior to that, Dr. Birnbaum held various management positions at the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth).

Dr. Birnbaum has broad relationships in industry and academia, and has published extensively on his work in drug development. His professional affiliations include the American Academy of Dermatology, Society of Investigative Dermatology, European Academy of Dermatology and Venereology, American Society for Dermatologic Surgery, and International Society of Dermatology. He is a member of the board of directors of Oculus Innovative Sciences, Inc. and is on the Science Advisory Boards of Evolva, NanoBio Corp, NexMed, Inc., Topica Pharmaceuticals, and Transport Pharmaceuticals.

He received a B.S. degree from Trinity College and a Ph.D in Pharmacology from the University of Wisconsin.

Excaliard Pharmaceuticals, Inc,(R) is delighted to have an individual with Jay's technical and business experience join the Board of Directors and looks forward to his many contributions.


'/>"/>
SOURCE Excaliard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
2. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
4. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
5. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
7. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
9. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
10. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
11. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... The threat of ... to work for a company involved in the underground testing of nuclear weapons. Years ... for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical ...
(Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
Breaking Medicine Technology: